AlphaValue Corporate Services has been commissioned and paid for by the covered companies and is deemed to constitute an acceptable minor non-monetary benefit as defined in MiFID II.






CNTY France Supergenerics Pharma €120m
We regard Crossject as a new entrant in the speciality pharma field. Its differentiating feature is its delivery mechanism, Zeneo, a pretty unique needle-free injection system. Crossject has completed clinical trials on a first well-known molecule, Methotrexate, with another six to go in the pipeline. Zeneo is the fruit of over 15 years of R&D. It is an automatic single-use pre-filled needle-free injection device to be used, for example, on the thigh or abdomen. The technology is based on a high-pressure injection allowing a drug to be administered rapidly (1/10 sec) into the tissue.

Jul 22nd, 2022 The update of our assumptions confirms a huge upside potential View Download
Jun 20th, 2022 A major breakthrough for Crossject View Download
Mar 29th, 2022 FY21: not very meaningful, as expected View Download
Dec 17th, 2021 New financing View Download
Sep 24th, 2021 H1 21: unsurprising (as usual) View Download
Aug 31st, 2021 EPS cut (2021: from € 0.18 to -0.28, 2022: from € 0.91 to 0.63) View Download
Aug 18th, 2021 EPS cut (2020: from € -0.32 to -0.49, 2021: from € 0.18 to 0.18) View Download
Jun 18th, 2021 Another good piece of news for the group View Download
Jun 17th, 2021 A licensing agreement for Zeneo Hydrocortisone in the US and Canada View Download
Mar 31st, 2021 FY20 unsuprising; waiting for more View Download
Dec 15th, 2020 A double bond issue View Download
Sep 21st, 2020 H1 20 no surprises, as usual View Download
May 22nd, 2020 No major changes after the release of the FY19 report View Download
Mar 29th, 2020 Meaningless FY19 results and product update View Download
Dec 23rd, 2019 Extra-financing to increase visibility View Download
Nov 20th, 2019 A €2.6m non-dilutive issue View Download
Oct 15th, 2019 Cooperation agreement with the US Department of Defense View Download
Sep 10th, 2019 H1 19: no surprise View Download
Jul 10th, 2019 Warrants to existing shareholders View Download
Jun 19th, 2019 A commercial success View Download
Mar 15th, 2019 Slowly but surely View Download
Feb 4th, 2019 Some extra non-dilutive financing View Download
Dec 21st, 2018 Success of the capital increase View Download
Nov 28th, 2018 A €3.9m capital increase View Download
Nov 22nd, 2018 Excellent news: production has resumed View Download
Oct 23rd, 2018 Bond conversion View Download
Sep 27th, 2018 H1 18: insignificant; some more time needed to reach the market View Download
Jul 13th, 2018 A convertible bond and potential options for existing shareholders View Download
May 17th, 2018 Business update View Download
Mar 22nd, 2018 On its way to reach the market… View Download
Feb 14th, 2018 A convertible bond and options for existing shareholders View Download
Feb 3rd, 2018 Orphan disease status for Zeneo® Midazolam in the US View Download
Dec 11th, 2017 Update on the company’s activities View Download
Sep 25th, 2017 H1 17: a new NTE in the pipeline...and further delays View Download
Apr 6th, 2017 The capital increase was successful View Download
Mar 13th, 2017 FY16 results - untelling (as expected) and a €4.3m capital increase View Download